Table 3.

Comparison Between Positive and Negative Serology Tests and LASSO for Early Lyme Disease Test-samples

LC-MS Run	2-Tier Serologya vs LASSO			IgM Immunoblot 2-Tier Serologya vs LASSO			IgG Immunoblot 2-Tier Serologya vs LASSO			IgM and IgG Immunoblot 2-Tier Serologya vs LASSO
	N	2-Tier %	LASSO % Pos.	N	IgM %	LASSO % Pos.	N	IgG %	LASSO % Pos.	N	IgM/IgG %	LASSO % Pos.
Subjects with Early Lyme Disease (n = 158)
Run 1 (n = 20)
Positive Serology	7	35	100	4	20	100	2	10	100	1	5	100
Negative Serology	13	65	92	16	80	94	18	90	94	19	95	95
Run 2 (n = 71)
Positive Serology	33	47	94	25	35	92	2	3	100	6	9	100
Negative Serology	38	53	95	46	65	96	69	97	94	65	91	94
Run 3 (n = 140)
Positive Serology	66	47	83	50	36	84	4	3	100	12	9	75
Negative Serology	74	53	85	90	64	84	136	97	84	128	91	85
Run 4 (n = 71)
Positive Serology	33	47	88	25	35	84	2	3	100	6	9	100
Negative Serology	38	53	92	46	65	94	69	97	90	65	91	89
Run 5 (n = 67)
Positive Serology	32	48	91	24	36	88	2	3	100	6	9	100
Negative Serology	35	52	77	43	64	81	65	97	83	61	91	82
C6-Positive Subjects (n = 22)
Positive Serology	9	41	100	6	27	100	1	5	100	2	9	100
Negative Serology	13	59	77	16	73	81	21	95	86	20	91	85

Abbreviations: CDC, Centers for Disease Control and Prevention; IgG, immunoglobulin G; IgM, immunoglobulin M; LC-MS, liquid chromatography-mass spectrometry; Pos., positive.

^a CDC 2-tier interpretation criteria were used [4]; however, all samples were tested by IgM immunoblots regardless of duration of illness or first-tier test result; 2-tier serology was performed using VIDAS followed by Marblot immunoblots.